| Literature DB >> 33653728 |
Alexandra Couto Oliveira1, Ilda Patrícia Ribeiro1,2,3,4, Luís Miguel Pires1, Ana Cristina Gonçalves2,3,4,5, Artur Paiva2,3,6, Catarina Geraldes2,3,4,5,7, Adriana Roque4,7, Ana Bela Sarmento-Ribeiro2,3,4,5,7, Joana Barbosa de Melo1,2,3,4, Isabel Marques Carreira8,2,3,4.
Abstract
Multiple myeloma (MM) genomic complexity reflects in the variable patients' clinical presentation. Genome-wide studies seem to be a reasonable alternative to identify critical genomic lesions. In the current study, we have performed the genomic characterisation of a Portuguese cohort of patients with MM by array comparative genomic hybridisation. Overall, the most frequently detected alterations were 13q deletions, gains of 1q, 19p, 15q, 5p and 7p and trisomy 9. Even though some identified genomic alterations were previously associated with a prognostic value, other abnormalities remain with unknown, but putative significance for patients' clinical practice. These genomic alterations should be further assessed as possible biomarkers. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: biomarkers; microarray analysis; multiple myeloma; tumour
Mesh：
Year: 2021 PMID： 33653728 DOI： 10.1136/jclinpath-2020-207204
Source DB: PubMed Journal: J Clin Pathol ISSN： 0021-9746 Impact factor: 3.411